منابع مشابه
Chapter 6 Therapeutic Uses
Many people remember vaguely that LSD and other psychedelic drugs were once used experimentally in psychiatry, but few realize how much and how long they were used. This was not a quickly rejected and forgotten fad. Between 1950 and the mid-1960s there were more than a thousand clinical papers discussing 40,000 patients, several dozen books, and six international conferences on psychedelic drug...
متن کاملOlibanum bezoar: complication of a traditional popular medicine.
In the Libyan Arab Jamahiriya, olibanum (frankincense) is commonly recommended as a part of the traditional popular medic cine for the treatment of some abdominal disease. Olibanum is used in Misurata as a chewing gum and is swallowed for the treatment of dyspepsia. Bezoars are large conglomerates of vegetables fibres, hairs or concretions of various substances loc cated in the stomach or small...
متن کاملInterleukin-6 as a therapeutic target.
Human IL6 is a cytokine produced by many cell types that has pleiotropic effects. In agreement, anti-IL6 therapy reduces inflammation, hepatic acute phase proteins, and anemia and has antiangiogenic effects. Blocking IL6 has demonstrated therapeutic efficacy with drug registration in Castleman disease and inflammatory diseases (rheumatoid arthritis) without major toxicity. Interestingly, the in...
متن کاملCorrection: Interleukin-6: a new therapeutic target
JSS has received financial compensation from and served on advisory boards for Roche and is an investigator in clinical trials of tocilizumab. RNM has received consulting fees from Chugai; served on an ad hoc advisory board for Roche; and was responsible for the planning and preparation for publication of the Phase II European (CHARISMA) trial of tocilizumab with and without methotrexate. A pat...
متن کاملInterleukin-6: a new therapeutic target
The therapeutic success of biological agents, especially the tumour necrosis factor (TNF) inhibitors, has opened a new chapter in the book of therapies for rheumatoid arthritis. Nevertheless, more than 50% of patients may not respond by > 50% improvement. New compounds have recently entered the treatment arena. One of these is rituximab, which depletes B cells, and another, abatacept, interfere...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The American Journal of the Medical Sciences
سال: 1862
ISSN: 0002-9629
DOI: 10.1097/00000441-186204000-00046